An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
AIM ImmunoTech announces the release of the next CEO Corner segment featuring an overview of Metastatic Pancreatic Cancer and the ongoing Phase 1b/2 clinical trial combining Ampligen® with Imfinzi® for the treatment of late-stage pancreatic cancer.
AIM ImmunoTech annuncia il lancio del prossimo segmento CEO Corner, che presenterà una panoramica sul Cancro al Pancreas Metastatico e lo studio clinico in corso di Fase 1b/2 che combina Ampligen® con Imfinzi® per il trattamento del cancro al pancreas in stadio avanzato.
AIM ImmunoTech anuncia el lanzamiento del próximo segmento de CEO Corner, que incluirá una visión general del Cáncer de Páncreas Metastásico y el ensayo clínico en curso de Fase 1b/2 que combina Ampligen® con Imfinzi® para el tratamiento del cáncer de páncreas en etapa tardía.
AIM ImmunoTech는 전이성 췌장암 개요와 말기 췌장암 치료를 위해 Ampligen®과 Imfinzi®를 결합한 1b/2상 임상 시험을 다루는 다음 CEO Corner 세그먼트 출시를 발표합니다.
AIM ImmunoTech annonce la sortie du prochain segment de CEO Corner présentant un aperçu du Cancer du Pancréas Métastatique et l'essai clinique en cours de phase 1b/2 associant Ampligen® à Imfinzi® pour le traitement du cancer du pancréas en phase avancée.
AIM ImmunoTech kündigt die Veröffentlichung des nächsten CEO Corner-Segments an, das einen Überblick über metastasierenden Pankreaskrebs und die laufende klinische Studie der Phase 1b/2 umfasst, die Ampligen® mit Imfinzi® für die Behandlung von fortgeschrittenem Pankreaskrebs kombiniert.
Positive
None.
Negative
None.
OCALA, Fla., April 25, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), today announced the next CEO Corner segment has been published on the Company’s website. For the CEO Corner segment, Thomas Equels, Chief Executive Officer of AIM ImmunoTech, gave an overview of Metastatic Pancreatic Cancer and the ongoing Phase 1b/2 clinical trial combining AIM’s Ampligen® (rintatolimod) with AstraZeneca’s anti-PD-L1 immune checkpoint inhibitor Imfinzi® (durvalumab) for the treatment of late-stage pancreatic cancer (the “DURIPANC Study”).
AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19. The Company’s lead product is a first-in-class investigational drug called Ampligen® (rintatolimod), a dsRNA and highly selective TLR3 agonist immuno-modulator with broad spectrum activity in clinical trials for globally important cancers, viral diseases and disorders of the immune system.
AIM ImmunoTech announced the release of the next CEO Corner segment featuring an overview of Metastatic Pancreatic Cancer and the ongoing Phase 1b/2 clinical trial.
What is the CEO Corner segment about?
The CEO Corner segment provides information on combining AIM's Ampligen® with AstraZeneca's Imfinzi® for the treatment of late-stage pancreatic cancer.
Who is the Chief Executive Officer of AIM ImmunoTech?
Thomas Equels is the Chief Executive Officer of AIM ImmunoTech.
What is the DURIPANC Study?
The DURIPANC Study is a Phase 1b/2 clinical trial combining Ampligen® with Imfinzi® for the treatment of late-stage pancreatic cancer.
